$VXRT Clinical studies: A Phase II trial of VXA-CoV2-1, our vaccine encoding both the S and the N proteins, is expected to start mid-year 2021 instead of 2Q. The delay is due to manufacturing issues at the Baltimore contract manufacturing facility, the same facility where other COVID-19 vaccine manufacturers have also reported issues. Manufacturing of our vaccines is currently underway at the Companys other manufacturing partner, and at our own GMP facility. We are also evaluating additional manufacturing partners both in the U.S. and abroad. Phase I/II studies of two S-only vaccine constructs targeting different variants are planned to begin in 3Q 2021. Boosting studies with previously vaccinated or infected subjects are also planned for 2H 2021. Trials in India and Latin America are expected to initiate in 2021.